BRCA Biomarkers
Merck, AstraZeneca Net European Approval for Adjuvant Lynparza in BRCA-Mutated Early Breast Cancer
The European Commission approved the PARP inhibitor for high-risk, early-stage HER2-negative breast cancer patients whose tumors harbor germline BRCA1/2 mutations.
AstraZeneca Q2 Oncology Sales Grow 14 Percent as Firm Awaits Key Precision Drug Regulatory Decisions
Premium
Following practice-changing ASCO data, the drugmaker anticipates US and EU regulatory decisions for Enhertu in HER2-low metastatic breast cancer by the end of the year.
EMA's CHMP Recommends Restricting Third-Line Ovarian Cancer Indication for Clovis' Rubraca
The committee said the indication in BRCA1/2-mutated ovarian cancer patients should be removed from the PARP inhibitor label based on negative confirmatory trial data.
Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients
After seeing patients with co-occurring biomarkers fail on a PARP inhibitor, but respond to checkpoint inhibitors, researchers are studying this further in larger cohorts.
Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response
Breast and ovarian cancers with BRCA1 promoter methylation changes showed poorer chemotherapy responses than those with genetic alterations in BRCA1 or BRCA2.